Effect of evening primrose oil and omega-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 1, 2011, Pages 72-79

  Zaitone, Sawsan A ^a   Moustafa, Yasser M ^a   Mosaad, Sarah M ^a   El Orabi, Naglaa F ^a  

^a Suez Canal University   (Egypt)

Author keywords

blood pressure; cardiovascular risk; celecoxib; evening primrose oil; n 3 polyunsaturated fatty acids; thrombogenesis

Indexed keywords

CELECOXIB; OMEGA 3 FATTY ACID; PRIMROSE OIL;

ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; HEART PROTECTION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS;

EID: 79960430595     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821c8353     Document Type: Article

References (68)

1. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr. 2008;19:102-107. (Pubitemid 351846442)
2. Hull MA. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer. 2005;41:1854-1863.
3. Schlichtiger J, Pekcec A, Bartmann H, et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol. 2010;160:1062-1071.
4. FitzGerald GA.COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
5. Brownstein JS, Sordo M, Kohane IS, et al. The tell-tale heart: populationbased surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE. 2007;2:e840.
6. Solomon SD, McMurray JJ, Pfeffer MA, et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080. (Pubitemid 40365348)
7. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX-2): the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96: 272-277. (Pubitemid 29036089)
8. RudicRD, BrinsterD, ChengY, et al.COX-2-derived prostacyclinmodulates vascular remodeling. Circ Res. 2005;96:1240-1247.
9. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2 derived prostaglandins. Circ Res. 2005;96:e1-e6.
10. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptor: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229. (Pubitemid 24185151)
11. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase. N Engl J Med. 2001;345:433-442.
12. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15. (Pubitemid 43121782)
13. Ghosh M,Wang H, Ai Y, et al. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARd activation. J Exp Med. 2007;204: 2053-2061. (Pubitemid 47360868)
14. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci. 2004;107:1-11. (Pubitemid 38932191)
15. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71:S179-S188.
16. Ait-Yahia D, Madani S, Savelli J-L, et al. Dietary fish protein lowers blood pressure and alters tissue polyunsaturated fatty acid composition in spontaneously hypertensive rats. Nutrition. 2003;19:342-346. (Pubitemid 36390129)
17. KogaT,Az-maT,YugeO.ProstaglandinE1 at clinically relevant concentrations inhibits aggregationofplateletsunder synergic interactionwithendothelial cells. Acta Anaesthesiol Scand. 2002;46:987-993. (Pubitemid 34953684)
18. Horrobin DF. Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res. 1992;31:163-194.
19. Fitzgerald SM, Brands MW. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab. 2000;279:E762-E768.
20. Hull R, Hirsh H, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681. (Pubitemid 13206049)
21. Hoffmann JJ, Meulendijk PN. Comparison of reagents for determining the activated partial thromboplastin time. Thrombos Haemostas. 1978;39: 640-645. (Pubitemid 9016356)
22. Piccione G, Grasso F, Fazio F, et al. The effect of physical exercise on the daily rhythm of platelet aggregation and body temperature in horses. Vet J. 2008;176:216-220. (Pubitemid 351405128)
23. Seth P, Kumari R, Dikshit M. Alterations in the free radical generation and nitric oxide release from rat peripheral polymorphonuclear leukocytes following thrombosis. Thromb Res. 1997;87:279-288. (Pubitemid 27381888)
24. Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009;206:2381-2395.
25. Muscara MN, Vergnolle N, Lovren F, et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol. 2000;129:1423-1430. (Pubitemid 30175715)
26. Rousseau D, Helies-Toussaint C, Moreau D, et al. Dietary n-3 PUFAs affect the blood pressure rise and cardiac impairments in a hyperinsulinemia rat model in vivo. Am J Physiol Heart Circ Physiol. 2003;285: H1294-H1302. (Pubitemid 37048188)
27. Matsuo N, Osada K, Kodama T, et al. Effects of g-linolenic acid and its positional isomer pinolenic acid on immune parameters of Brown Norway rats. Prostaglandins Leukot Essent Fatty Acids. 1996;55:223-229. (Pubitemid 26384199)
28. Yan C, MiaoW, Ying Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116: 1391-1399.
29. Francesca S, Andrew D, Patricia V, et al. Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1751-R1760.
30. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation. 2005;111:249. (Pubitemid 40165327)
31. Westgate EJ, FitzGerald GA. Pulmonary embolism in awoman taking oral contraceptives and valdecoxib. PLOS Med. 2005;2:e197.
32. Bertagnolli M, Eagle C, Zauber A, et al; Hawk ET for the APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884. (Pubitemid 44315980)
33. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med. 2006;119:552-559. (Pubitemid 44063485)
34. Solomon SD, Wittes J, Finn PV, et al.; Hawk E, Cross Trial Safety Assessment Group. Cardiovascular risk of Celecoxib in 6 randomized placebo-controlled trials. The cross trial safety analysis. Circulation. 2008;117:2104-2113. (Pubitemid 351572169)
35. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296: 539-541. (Pubitemid 34408674)
36. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2: 201-207.
37. ChengY,WangM,YuY, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391-1399.
38. Seta F, Chung AD, Turner PV, et al. Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1751-R1760.
39. White BW. Cardiovascular effects of cyclooxygenase-inhibitors. Hypertension. 2007;49:408-410.
40. Salinas G, Rangasetty UC, Uretsky BF, et al. The cyclooxygenase 2 (COX-2) story: itââ,â.,¢s time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007;12:98-111.
41. Fronza M, Wrasse M, Brum Junior L, et al. Evaluation of the changes on hemostatic parameters induced by valdecoxib in male Wistar rats. Rev Bras Hematol Hemoter. 2006;28:28-32. (Pubitemid 44243112)
42. Engler MM, Engler MB, Erickson SK, et al. Dietary gamma-linolenic acid lowers blood pressure and alters aortic reactivity and cholesterol metabolism in hypertension. J Hypertens. 1992;10:1197-1204.
43. St. Louis C, Lee RMKW, Rosenfeld J, et al. Antihypertensive effect of g-linolenic acid in spontaneously hypertensive rats. Hypertension. 1992; 19:II-111-II-115.
44. Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, antiarrhythmic, anti-hypertensive, antiatherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 2008;7:37-54.
45. Katzenschlager R, Weiss K, Rogatti W, et al. Interaction between prostaglandin E1 and nitric oxide (NO). Thromb Res. 1991;62:299-304.
46. Engler MM, Schambelan M, Engler MB, et al. Effects of dietary gammalinolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. Proc Soc Exp Biol Med. 1998;218:234-237.
47. Yu Z, Ng VY, Su P, et al. Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther. 2006;317:732-738.
48. Sarkis A, Roman RJ. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab. 2004;5:245-256. (Pubitemid 38735779)
49. Engler MM, Engler MB. The effects of dietary evening primrose, black currant, borage and fungal oils on plasma hepatic and vascular tissue fatty acid composition in the spontaneously hypertensive rat. Nutr Res. 1998; 18:1533-1544. (Pubitemid 28421609)
50. Cruz JPDL, Romero MM, Carmona JA, et al. Effect of evening primrose oil on platelet aggregation in rabbits fed an atherogenic diet. Thromb Res. 1997;87:141-149. (Pubitemid 27333271)
51. Guivernau M, Meza N, Barja P, et al. Clinical and experimental study on the long-term effect of dietary gamma-linolenic acid on plasma lipids, platelet aggregation, thromboxane formation, and prostacyclin production. Prostaglandins Leukot Essent Fatty Acids. 1994;51:311-316. (Pubitemid 24327639)
52. Li D. Omega-3 fatty acids and non-communicable diseases. Chin Med J (Engl). 2003;116:453-458. (Pubitemid 36432776)
53. Lands WE, Libelt B, Morris A, et al. Maintenance of lower proportions of (n26) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n23) fatty acids. Biochim Biophys Acta. 1992; 1180:147-162.
54. Culp BR, Bradley TG, Lands WE. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med. 1979;3: 269-278. (Pubitemid 10218349)
55. BayonY,CrosetM,DavelooseD,et al.Effect of specificphospholipidmolecular species incorporated in human platelet membranes on thromboxane A2/ prostaglandin H2 receptors J Lipid Res. 1995 36 47-56.
56. He K, Song Y, Daviglus M, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. 2004;109:2705-2711. (Pubitemid 38737914)
57. Studer M, Briel M, Leimenstoll B, et al. Effect on different antilipidemic agents and diets on mortality. A systematic review. Arch Intern Med. 2005; 165:725-730. (Pubitemid 40569423)
58. Albert C, Campos H, Stampfer M, et al. Blood levels of long chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346: 1113-1118. (Pubitemid 34984601)
59. Kramer HJ, Stevens J, Grimminger F, et al. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52:1211-1217. (Pubitemid 26355296)
60. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002;277:8755-8758. (Pubitemid 34952937)
61. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol. 2000;34:137-168. (Pubitemid 30320960)
62. Needleman P, Raz A, Minkes MS, et al. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA. 1979;76:944-948. (Pubitemid 9130979)
63. Miyajima T, Tsujino T, Saito K, et al. Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res. 2001;24: 537-542. (Pubitemid 33048920)
64. Mori TA,Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on forearm vascular reactivity of the microcirculation in hyperlipidaemic, overweight men. Circulation. 2000; 102:1264-1269.
65. Dona M, Fredman G, Schwab JM, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counter-regulates leukocytes and platelets. Blood. 2008;112:848-855.
66. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461:1287-1291.
67. Croset M, Lagarde M. In vitro incorporation and metabolism of eicosapentaenoic and docosahexaenoic acids in human platelets-effect on aggregation. Thromb Haemost. 1986;56:57-62. (Pubitemid 16015917)
68. Beilin LJ, Mori TA. Dietary w-3 fatty acids. In: Whelton PK, He J, Louis GT, eds. Lifestyle Modification for the Prevention and Treatment of Hypertension. New York, NY: Marcel Dekker; 2003:275-300.